| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1996;93:1826-1835.)
© 1996 American Heart Association, Inc.
Articles |
LDL-Apheresis Atherosclerosis Regression Study (LAARS)
Effect of Aggressive Versus Conventional Lipid Lowering Treatment on Coronary Atherosclerosis
From the Departments of Internal Medicine (A.A.K., A.F.H.S.) and Cardiology (W.R.M.A., T.v.d.W., G.J.H.U.), University Hospital Nijmegen, and the Departments of Diagnostic Radiology (J.H.C.R.) and Cardiology (A.V.G.B.) (Heart Core Laboratory), University Hospital Leiden, the Netherlands.
Correspondence to A.F.H. Stalenhoef, MD, Department of Internal Medicine, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, the Netherlands.
Background Intensive lipid lowering may retard the progression of coronary atherosclerosis. LDL-apheresis has the potential to decrease LDL cholesterol to very low levels. To assess the effect of more aggressive lipid lowering with LDL-apheresis, we set up a randomized study in men with hypercholesterolemia and severe coronary atherosclerosis.
Methods and Results For 2 years, 42 men were treated with either biweekly LDL-apheresis plus medication or medication alone. In both groups a dose of simvastatin of 40 mg per day was administered. Baseline (mean±SD) LDL cholesterol was 7.8±1.9 mmol·L-1 and 7.9±2.3 mmol·L-1 in the apheresis and medication groups, respectively. The mean reduction in LDL cholesterol was 63% (to 3.0 mmol·L-1) and 47% (to 4.1 mmol·L-1), respectively. Primary quantitative coronary angiographic end points were changes in average mean segment diameter and minimal obstruction diameter. No differences between the apheresis and medication groups were found in mean segment diameter (-0.01±0.16 mm versus 0.03±0.16 mm, respectively) or in minimal obstruction diameter (-0.01±0.13 mm versus 0.01±0.11 mm, respectively), expressed as means per patient. On the basis of coronary segment, mean percent stenosis of all lesions showed a tendency to decrease; only in the apheresis group more minor lesions disappeared in comparison to the medication group. On bicycle exercise tests, the time to 0.1 mV ST-segment depression increased significantly by 39% and the maximum level of ST depression decreased significantly by 0.07 mV in the apheresis group versus no changes in the medication group.
Conclusions Two years of lipid lowering both with medication alone or LDL-apheresis with medication showed angiographic arrest of the progression of coronary artery disease. However, more aggressive treatment induced functional improvement, which may precede anatomic changes.
Key Words: angiography • atherosclerosis • coronary disease • apheresis • lipids • lipoproteins
This article has been cited by other articles:
 |
|
 |
|
  O C Maguire, D Mc Carthy, and S K Cunningham The effect of plasmapheresis on the concentration of certain plasma proteins: a case identified by an inaccurate LDL-cholesterol estimation Ann Clin Biochem, July 1, 2008; 45(4): 436 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S van Wissen, T J Smilde, M D Trip, T. de Boo, J J P Kastelein, and A F H Stalenhoef Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia Heart, August 1, 2003; 89(8): 893 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Sulowicz and T. Stompor LDL-apheresis and immunoadsorption: novel methods in the treatment of renal diseases refractory to conventional therapy Nephrol. Dial. Transplant., July 1, 2003; 18(90005): v59 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Corvol, A. Bouzamondo, M. Sirol, J.-S. Hulot, P. Sanchez, and P. Lechat Differential Effects of Lipid-Lowering Therapies on Stroke Prevention: A Meta-analysis of Randomized Trials Arch Intern Med, March 24, 2003; 163(6): 669 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Matsuzaki, K. Hiramori, T. Imaizumi, A. Kitabatake, H. Hishida, M. Nomura, T. Fujii, I. Sakuma, K. Fukami, T. Honda, et al. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: The Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART) J. Am. Coll. Cardiol., July 17, 2002; 40(2): 220 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Ravnskov Is atherosclerosis caused by high cholesterol? QJM, June 1, 2002; 95(6): 397 - 403. [Full Text] [PDF]
|
|
|
|
 |
|
 N. K. Thakur, T. Hayashi, D. Sumi, H. Kano, T. Tsunekawa, and A. Iguchi HMG-CoA reductase inhibitor stabilizes rabbit atheroma by increasing basal NO and decreasing superoxide Am J Physiol Heart Circ Physiol, July 1, 2001; 281(1): H75 - H83. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Stein and O. Stein Does Therapeutic Intervention Achieve Slowing of Progression or Bona Fide Regression of Atherosclerotic Lesions? Arterioscler Thromb Vasc Biol, February 1, 2001; 21(2): 183 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Nose, K.-i. Nakata, M. Yoshikawa, G. V. Letsou, A. Fujisawa, E. Wolner, and H. Schima Development of a totally implantable biventricular bypass centrifugal blood pump system Ann. Thorac. Surg., August 1, 1999; 68(2): 775 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.-C. Schoebel, T. W. Jax, B.-E. Strauer, M. Leschke, and W. R. M. A. A. J. v. B. A. H. Z. J. W. J. A. V. G. van der Werf Functional Evaluation of Lipid-Lowering Therapy by Pravastatin • Response Circulation, May 12, 1998; 97(18): 1874 - 1875. [Full Text]
|
|